Accueil/Actions/RLMD

RLMD

USD

Relmada Therapeutics Inc. Common Stock

$2.770+0.560 (25.339%)

Prix en Temps Réel

Healthcare

Biotechnologie

États-Unis

Graphique des Prix

Loading Chart...

Métriques Clés

Métriques de Marché

Fondamentaux de l'Entreprise

Statistiques de Trading

Métriques de Marché

Ouverture

$2.210

Haut

$2.810

Bas

$2.190

Volume

0.98M

Fondamentaux de l'Entreprise

Capitalisation Boursière

91.9M

Industrie

Biotechnologie

Pays

United States

Statistiques de Trading

Volume Moyen

0.74M

Bourse

NCM

Devise

USD

Intervalle sur 52 Semaines

Bas $0.24Actuel $2.770Haut $3.5

Actualités Connexes

4 nov. 2025 · 12:09

GlobeNewswire

Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

CORAL GABLES, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for oncology and

Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

4 nov. 2025 · 12:01

GlobeNewswire

Relmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder Cancer

Announces NDV-01 9-Month Follow-up Safety and Efficacy Data in NMIBC FDA feedback supports 2 potential registrational trials – 1) a registrational trial in 2nd line refractory BCG-unresponsive NMIBC, and 2) a randomized